About this Research Topic
As of the 21st century, cancer is arguably the most challenging and complex disease.
Chemotherapy is an essential element of cancer therapy. But, approximately, 54,000 (oral), 236,740 (lung), 290,560 (breast), 19,880 (ovarian), 25,050 (brain) related new cases, and 11,230 (oral), 130,180 (lung), 43,780 (breast), 12,810 (ovarian), 18,280 (brain) related deaths are expected in 2023.
So, there is a need to boost the development of novel approaches and smart drug delivery strategies to tackle breast, brain, lung, and ovarian cancer.
At present, the results of chemotherapy are far from satisfactory, due also to the complex pathophysiology of these types of cancers.
That’s why nano-mediated multi-drug delivery systems have revolutionized the landscape of cancer treatment because of their selective targeting of cancerous cells and non-toxicity to non-cancerous cells. They have more therapeutic potential for the brain, lung, breast, lymphoma, ovarian, leukemia, oral and several others.
To date, various nano-mediated delivery systems have been designed and only some of them are approved by USFDA. Moreover, the success of nano-mediated delivery systems may hinder the side effects of traditional therapies. From this perspective, nano-mediated delivery systems have good potential for cancer treatment and/or management.
This special issue aims to emphasize the development of various nano-mediated delivery systems for cancer therapies.
The objective of the current special issue is to publish original research, review and case studies from authors who are interested in nano-mediated delivery systems and in delivering new insights for the treatment of brain, breast, lung and ovarian cancer, by addressing the combined application of drug therapy with (but not limited to):
nanoparticles, liposomes, quantum dots, solid lipid nanoparticles, niosomes, nanocapsules, nanocomposites, carbon nanotubes, dendrimers, nanolipid carriers and several others.
Chemotherapy is an essential element of cancer therapy. But, approximately, 54,000 (oral), 236,740 (lung), 290,560 (breast), 19,880 (ovarian), 25,050 (brain) related new cases, and 11,230 (oral), 130,180 (lung), 43,780 (breast), 12,810 (ovarian), 18,280 (brain) related deaths are expected in 2023.
So, there is a need to boost the development of novel approaches and smart drug delivery strategies to tackle breast, brain, lung, and ovarian cancer.
At present, the results of chemotherapy are far from satisfactory, due also to the complex pathophysiology of these types of cancers.
That’s why nano-mediated multi-drug delivery systems have revolutionized the landscape of cancer treatment because of their selective targeting of cancerous cells and non-toxicity to non-cancerous cells. They have more therapeutic potential for the brain, lung, breast, lymphoma, ovarian, leukemia, oral and several others.
To date, various nano-mediated delivery systems have been designed and only some of them are approved by USFDA. Moreover, the success of nano-mediated delivery systems may hinder the side effects of traditional therapies. From this perspective, nano-mediated delivery systems have good potential for cancer treatment and/or management.
This special issue aims to emphasize the development of various nano-mediated delivery systems for cancer therapies.
The objective of the current special issue is to publish original research, review and case studies from authors who are interested in nano-mediated delivery systems and in delivering new insights for the treatment of brain, breast, lung and ovarian cancer, by addressing the combined application of drug therapy with (but not limited to):
nanoparticles, liposomes, quantum dots, solid lipid nanoparticles, niosomes, nanocapsules, nanocomposites, carbon nanotubes, dendrimers, nanolipid carriers and several others.
Keywords: Nanotherapeutic, Brain cancer, Breast cancer, Quantum dots, Ovarian cancer, Nanoparticles, Liposomes
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
